Page 849 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 827

Intestinal tumors (Continued) Intravascular (angiotropic, Large-gauge needle, 127
abdominal radiographs and ultrasound, Intravascular metastases, 54 Large granular lymphoma, 143f
angioendotheliomatosis) lymphoma, 690
Large intestine, surgery for, 466–467
463–464, 464f
VetBooks.ir colonoscopy, 464–465 Intrinsic mutagen, 1 Larynx, cancer of, 505
endoscopy, 464–465
clinical signs of, 505
Invasive cutaneous tumor, 287t
exploratory laparotomy, 465 Invasive soft tissue sarcoma, 287t comparative aspects of, 507
laparoscopy, 464–465 Invasive thyroid carcinomas, 576–577 diagnostic techniques for, 505–506,
thoracic radiographs, 464 Invasiveness, 69t 505f–506f
incidence and risk factors for, 460 Investigational new drugs (INDs), 345 history for, 505
molecular aspects of, 462 Ionization, direct/indirect effects of, 209 incidence of, 505
natural behavior of, 461–462 Ionizing radiation natural behavior of, 505
pathology and natural behavior of, canine osteosarcoma and, 524–525 pathology of, 505
461–462, 461f as carcinogen, 212 prognosis of, 506
adenomatous polyps and effects of, 209 risk factors for, 505
adenocarcinoma, 461–462, 461f skin cancer and, 352 therapy for, 506
leiomyomas, leiomyosarcomas, and IRB. see Institutional Review Board Laser ablation, 179
GISTs, 462 IRE. see Irreversible electroporation Laser therapy, 336
lymphoma, 461 Iridociliary epithelial tumors, 682 Lateral bulla osteotomy, 361
mast cell tumors, 462 Iron, Prussian blue stain for, 129 LDDST. see Low-dose dexamethasone
physical examination for, 463 Irreversible electroporation (IRE), 180 suppression test
prognosis for, 465–467 Isoflavones, 309 Lean body mass wasting, 301
prognostic factors for, 467 Isolated limb perfusion (ILP), in canine Leiomyomas, 462
therapy for, 465–467 osteosarcoma, 540 cell characteristics in, 139
chemotherapy, 467 ITAP. see Intraosseous transcutaneous immunohistochemical markers/panels for,
radiation therapy, 467 amputation prosthesis 72t–73t
surgery for, 465–467, 466f ITD. see Internal tandem duplication as uterine tumors, 600, 601f
Intraarterial chemotherapy, 176–177 ITP. see Immune-mediated thrombocytopenia Leiomyosarcomas, 462
Intracapsular wound margin, 167t IV ketamine, 295–296 cell characteristics in, 139
Intracorporeal intraoperative radiation immunohistochemical markers/panels for,
therapy, for canine osteosarcoma, 539 J 72t–73t
Intracranial tumors, 657–665 Jamshidi bone biopsy needle, 529, 530f Lentivirus, 252t
in cats, 658, 658t Joule, 209 FIV as, 25
classification of, 657 Journal of Veterinary Internal Medicine, Leukemia
clinical signs of, 658–660, 659f CARES reporting guidelines, 93 cytogenetic analysis for, 147
diagnosis of, 660–662 Juxtacortical osteosarcoma, 550 definition of, 63
biopsy and pathology of, 661–662 FIV infection and, 25
cerebrospinal fluid analysis, 662 K Leukotriene synthase, 308f
diagnostic imaging, 660–661, 660f–661f Kaplan-Meier curve Leydig cell tumor, 627t
minimum database, 660 for liposarcoma, 408f Lidocaine, 296, 299t
in dogs, 657–658, 658t for soft tissue sarcomas, 417f Ligand/DNA conjugate, 252t
epidemiology of, 657 Kaposi’s sarcoma, 26 Limb salvage, for canine osteosarcoma,
history of, 658–660 Keratin staining, 133 534–538
incidence of, 657 Keratinization, 133 nonsurgical, 539–542
pathophysiology of, 658–660 Keratitis, 16 intracorporeal and extracorporeal
prognosis for, 662–665 Ketamine, 295–296, 299t intraoperative radiation therapy in,
treatment of, 662–665 Ketoprofen, 293t–294t 539
chemotherapy, 662–663 Ki-67, 385–386 isolation of limb circulation and
novel therapeutics, 665 Kinase perfusion in, 540
palliative care, 662, 663f inhibition of, 261–262 stereotactic radiation therapy in,
radiation therapy, 664–665 overexpression of, 260 539–540, 539f–540f
surgery, 663–664 KIT dysregulation, in MCT prognosis, 386 summary of outcome after, 540–541
Intracytoplasmic cyclooxygenase-2 (COX-2), KIT mutation, 260 Limb sparing surgery, for osteosarcoma, 170
597 KIT protein, 628 Limbal (epibulbar) melanomas, 678, 678f
Intraluminal stent placement, for malignant Linear quadratic formalism, biologic effective
urethral obstruction, 175 L dose and, 214–215
Intranasal anaplastic carcinoma, 497f Labeling, of biopsy sample, 62 Lingual melanoma, 370f
Intranasal tumor, 287t Laminin, 628 Lingual tumors, 445–446
Intraoperative chemotherapy, 170 Laparoscopic adrenalectomy, for prognosis for, 446
Intraosseous transcutaneous amputation feline pituitary-dependent surgical resection for, 446
prosthesis (ITAP), for limb salvage, 541 hyperadrenocorticism, 568–569 Lipid
Intravasation, 52–53 Laparoscopy, 161 histochemical stains specific for, 71t
conclusion of, 53 for intestinal tumors, 464–465 parenteral solutions proportions for, 306